Advertisement

Endocrine

, Volume 52, Issue 3, pp 458–480 | Cite as

Systematic review and meta-analysis of vildagliptin for treatment of type 2 diabetes

  • Eleni Bekiari
  • Chrysoula Rizava
  • Eleni Athanasiadou
  • Konstantinos Papatheodorou
  • Aris Liakos
  • Thomas Karagiannis
  • Maria Mainou
  • Maria Rika
  • Panagiota Boura
  • Apostolos Tsapas
Meta-Analysis

Abstract

This systematic review and meta-analysis provides an update on the efficacy and safety of vildagliptin for treatment of type 2 diabetes mellitus (T2DM). We searched MEDLINE, COCHRANE, EMBASE and the drug manufacturer’s website for randomised controlled trials of vildagliptin in patients with T2DM. Sixty-nine studies (28,006 patients) were included in the meta-analysis. Compared with placebo vildagliptin reduced HbA1c (weighted mean difference WMD −0.69 %; 95 % CI −0.83 to −0.56 %; I 2 = 82 %), and it was as effective as other antidiabetic agents (WMD −0.01 %; 95 % CI −0.16 to 0.14 %; I 2 = 93 %), without increasing the risk for hypoglycemia (OR 0.83; 95 % CI 0.59 to 1.16; I 2 = 0 % vs. placebo, and OR 0.19; 95 % CI 0.15 to 0.24; I 2 = 78 % versus active comparators). However, it was associated with an increase in the incidence of arthralgia compared with other comparators (OR 1.23; 95 % CI 1.02 to 1.48; I 2 = 0 %). On the contrary, vildagliptin did not increase the incidence of pancreatitis (OR 0.97; 95 % CI 0.37 to 2.53; I 2 = 0 %), serious adverse events (OR 0.98; 95 % CI 0.88 to 1.09; I 2 = 0 %) or death (OR 1.10, 95 % CI 0.75 to 1.61; I 2 = 0 %). Finally, odds ratio (OR) for heart failure, and overall cardiovascular and cerebrovascular events was 0.77 (95 % CI 0.46 to 1.30; I 2 = 0 %) and 0.91 (95 % CI 0.73 to 1.14; I 2 = 0 %), respectively. Vildagliptin is an effective and safe therapeutic option for patients with T2DM, both as monotherapy and as add-on treatment.

Keywords

Vildagliptin DPP-4 inhibitors Systematic review Meta-analysis 

Notes

Acknowledgement

This work was partly supported by Novartis Pharmaceuticals Corporation. All authors participated in the development and writing of the article, approved the final manuscript for publication, and take full responsibility for the content of the article.

Compliance with ethical standards

Conflicts of interest

A.T. has received lecture or consultancy fees from AstraZeneca, Boehringer Ingelheim and MSD, and research support from Novartis, Novo Nordisk and Sanofi. E.A. has received research support from Novartis. The remaining authors declare no competing interests.

Supplementary material

12020_2015_841_MOESM1_ESM.doc (670 kb)
Supplementary material 1 (DOC 670 kb)

References

  1. 1.
    International Diabetes Federation Diabetes Atlas (Sixth edition). https://www.idf.org/sites/default/files/EN_6E_Atlas_Full_0.pdf. Accessed 17.11.2015
  2. 2.
    S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A.L. Peters, A. Tsapas, R. Wender, D.R. Matthews, Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58(3), 429–442 (2015)PubMedCrossRefGoogle Scholar
  3. 3.
    H. Park, C. Park, Y. Kim, K.L. Rascati, Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis. Ann. Pharmacother. 46(11), 1453–1469 (2012)PubMedCrossRefGoogle Scholar
  4. 4.
    L. Cai, Y. Cai, Z.J. Lu, Y. Zhang, P. Liu, The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials. J. Clin. Pharm. Ther. 37(4), 386–398 (2012)PubMedCrossRefGoogle Scholar
  5. 5.
    A. Schweizer, S. Dejager, J.E. Foley, A. Couturier, M. Ligueros-Saylan, W. Kothny, Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population. Diabetes Obes. Metab. 12(6), 485–494 (2010)PubMedCrossRefGoogle Scholar
  6. 6.
    J. Higgins, S. Green. Missing standard deviations. In: Cochrane Handbook for Systematic Reviews of Interventions. p. 485. (2008)Google Scholar
  7. 7.
    M.J. Sweeting, A.J. Sutton, P.C. Lambert, What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat. Med. 23(9), 1351–1375 (2004)PubMedCrossRefGoogle Scholar
  8. 8.
    J. Higgins, S. Green. Identifying and measuring heterogeneity. In: Cochrane Handbook for Systematic Reviews of Interventions. p. 277. (2008)Google Scholar
  9. 9.
    J. Rosenstock, S.W. Kim, M.A. Baron, R.P. Camisasca, F. Cressier, A. Couturier, S. Dejager, Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes. Metab. 9(2), 175–185 (2007)PubMedCrossRefGoogle Scholar
  10. 10.
    D.A. D’Alessio, A.M. Denney, L.M. Hermiller, R.L. Prigeon, J.M. Martin, W.G. Tharp, M.L. Saylan, Y. He, B.E. Dunning, J.E. Foley, R.E. Pratley, Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. J. Clin. Endocrinol. Metab. 94(1), 81–88 (2009)PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    M. Diamant, M. Poelma, D.L. Goede, L.W. Van Golen, R.E. Van Genugten, E.M. Eekhoff, A. Schweizer, R.J. Heine, J.E. Foley, G. Nijpels, M.C. Bunck. One-year vildagliptin, compared to placebo, treatment does not affect markers of bone resorption and calcium homeostasis in drug-naive patients with type 2 diabetes and mild hyperglycemia. Paper presented at the The American Diabetes Association 70th Annual Scientific Sessions, Orlando, FloridaGoogle Scholar
  12. 12.
    Y. Su, Y.L. Su, L.F. Lv, L.M. Wang, Q.Z. Li, Z.G. Zhao, Randomized controlled clinical trial of a combination therapy of vildagliptin plus an alpha-glucosidase inhibitor for patients with type II diabetes mellitus. Exp Ther Med 7(6), 1752–1756 (2014)PubMedPubMedCentralGoogle Scholar
  13. 13.
    Y. Su, Y.L. Su, L.F. Lv, L.M. Wang, Q.Z. Li, Z.G. Zhao, A randomized controlled clinical trial of vildagliptin plus metformin combination therapy in patients with type II diabetes mellitus. Exp Ther Med 7(4), 799–803 (2014)PubMedPubMedCentralGoogle Scholar
  14. 14.
    M. Takihata, A. Nakamura, Y. Terauchi, Comparative study of three DPP-4 inhibitors, namely sitagliptin, vildagliptin, and alogliptin, in Japanese type 2 diabetic patients: The COSVA randomized, controlled trial. Diabetes 63, A264 (2014)Google Scholar
  15. 15.
    C.J. Li, Q. Yu, P. Yu, Q.M. Zhang, M. Ding, X.J. Liu, D.M. Yu, Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes. Exp. Clin. Endocrinol. Diabetes 122(8), 469–476 (2014)PubMedCrossRefGoogle Scholar
  16. 16.
    T. Forst, M. Dworak, C. Berndt-Zipfel, A. Loffler, I. Klamp, M. Mitry, A. Pfutzner, Effect of vildagliptin on postprandial proinsulin processing in the beta-cell of patients with type 2 diabetes mellitus. Diabetes 62, A568 (2013)Google Scholar
  17. 17.
    T. Forst, M. Dworak, C. Berndt-Zipfel, A. Loffler, I. Klamp, M. Mitry, A. Pfutzner, Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the beta cell of patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 15(6), 576–579 (2013)PubMedCrossRefGoogle Scholar
  18. 18.
    C. Filozof, Corrigendum to A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet. Med. 30(5), 632 (2013)CrossRefGoogle Scholar
  19. 19.
    G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, A. D’Angelo, A.F. Cicero, P. Maffioli, Evaluation of the positive effects on insulin-resistance and beta-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacol. Res. 73, 20–26 (2013)PubMedCrossRefGoogle Scholar
  20. 20.
    B. Bhandare, V. Satyanarayana, J. Adhikary, A comparative study to evaluate the efficacy and safety of Vildagliptin as an add-on therapy to a low-dose Metformin vs an uptitration of Metformin in type 2 DM patients. Int. J. Pharm. Sci. Rev. Res. 22(2), 116–120 (2013)Google Scholar
  21. 21.
    C. Berndt-Zipfel, G. Michelson, I. Klamp, M. Mitry, A. Pfutzner, T. Forst, Vildagliptin in addition to metformin improves retinal arteriolar wall to lumen ratio and erythrocyte flexibility in patients with type 2 diabetes mellitus. Diabetes 62, A156–A157 (2013)Google Scholar
  22. 22.
    C. Berndt-Zipfel, G. Michelson, M. Dworak, M. Mitry, A. Loffler, A. Pfutzner, T. Forst, Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus—results from an exploratory study. Cardiovasc. Diabetol. 12(1), 59 (2013)PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    M. Barbieri, M.R. Rizzo, R. Marfella, V. Boccardi, A. Esposito, A. Pansini, G. Paolisso, Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis 227(2), 349–354 (2013)PubMedCrossRefGoogle Scholar
  24. 24.
    M. Abe, Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis. Blood Purif. 34(3–4), 261 (2013)Google Scholar
  25. 25.
    I. Zografou, C. Sampanis, A. Papageorgiou, B. Nikolaidou, P. Doukelis, D. Papadopoulou, M. Doumas, S. Douma, The combination therapy with metformin and vildagliptin decreases lymphocytes count in patients with type 2 diabetes mellitus. Diabetes 61, A600 (2012)Google Scholar
  26. 26.
    M.R. Rizzo, M. Barbieri, R. Marfella, G. Paolisso, Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care 35(10), 2076–2082 (2012)PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    C. Pan, X. Xing, P. Han, S. Zheng, J. Ma, J. Liu, X. Lv, J. Lu, G. Bader, Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 14(8), 737–744 (2012)PubMedCrossRefGoogle Scholar
  28. 28.
    V. Lukashevich, M. Wang, S. Del Prato, M. Araga, W. Kothny, Vildagliptin efficacy and safety in patients with type 2 diabetes inadequately controlled on dual metformin plus sulfonylurea therapy. Diabetologia 55, S353 (2012)Google Scholar
  29. 29.
    V. Lukashevich, P. Kozlovski, J. Foley, W. Kothny, Vildagliptin combined with insulin reduces HBA1C without increasing risk of hypoglycemia and weight gain in patients with type 2 diabetes mellitus. Diabetes 61, A254 (2012)Google Scholar
  30. 30.
    P. Kozlovski, J. Foley, Q. Shao, V. Lukashevich, W. Kothny, Improved glycaemic control without increased hypoglycaemia incidence and weight gain with insulin-vildagliptin combination therapy in Asian patients with type 2 diabetes. Diabetologia 55, S355 (2012)Google Scholar
  31. 31.
    W. Kothny, M. Wang, Q. Shao, P.H. Groop, V. Lukashevich, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes mellitus and moderate or severe renal insufficiency. Diabetes 61, A253 (2012)Google Scholar
  32. 32.
    W. Kothny, Q. Shao, P.H. Groop, V. Lukashevich, One-year safety, tolerability and efficacy of vildagliptin in patients with type 2 diabetes and moderate or severe renal impairment. Diabetes Obes. Metab. 14(11), 1032–1039 (2012)PubMedCrossRefGoogle Scholar
  33. 33.
    W. Kothny, P. Kozlovski, J. Foley, Q. Shao, V. Lukashevich, Vildagliptin added to once or twice daily insulin regimens improves glycaemic control without increasing risk of hypoglycaemia and weight gain in patients with type 2 diabetes. Diabetologia 55, S354 (2012)Google Scholar
  34. 34.
    N.H. Kim, Y.A. Sung, C.W. Ahn, S.W. Park, S. Lim, C.H. Kim, D.S. Kim, Y.G. Shin, K.J. Ahn, J.H. Kim, S.H. Baik, Efficacy and safety of add-on vildagliptin to metformin in comparison to uptitrating metformin therapy. Diabetes 61, A297 (2012)Google Scholar
  35. 35.
    H. Gilet, J.B. Gruenberger, G. Bader, M. Viala-Danten, Demonstrating the burden of hypoglycemia on patients’ quality of life in diabetes clinical trials: measurement considerations for hypoglycemia. Value Health 15(8), 1036–1041 (2012)PubMedCrossRefGoogle Scholar
  36. 36.
    J. Foley, P. Kozlovski, V. Lukashevich, W. Kothny, Vildagliptin improves a chronic effect on beta cell function when added to insulin therapy. Diabetologia 55, S355 (2012)Google Scholar
  37. 37.
    G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, A. D’Angelo, A.F. Cicero, P. Maffioli, Vildagliptin action on some adipocytokine levels in type 2 diabetic patients: a 12-month, placebo-controlled study. Expert Opin. Pharmacother. 13(18), 2581–2591 (2012)PubMedCrossRefGoogle Scholar
  38. 38.
    G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, L. Bianchi, A. Bonaventura, D. Romano, A.F. Cicero, P. Maffioli, Vildagliptin added to metformin on beta-cell function after an euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetic patients. Diabetes 61, A596 (2012)Google Scholar
  39. 39.
    G. Derosa, P.D. Ragonesi, A. Carbone, E. Fogari, L. Bianchi, A. Bonaventura, D. Romano, A.F. Cicero, P. Maffioli, Vildagliptin added to metformin on beta-cell function after a euglycemic hyperinsulinemic and hyperglycemic clamp in type 2 diabetes patients. Diabetes Technol Ther 14(6), 475–484 (2012)PubMedCrossRefGoogle Scholar
  40. 40.
    M.C. Bunck, M. Poelma, E.M. Eekhoff, A. Schweizer, R.J. Heine, G. Nijpels, J.E. Foley, M. Diamant, Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients. J Diabetes 4(2), 181–185 (2012)PubMedCrossRefGoogle Scholar
  41. 41.
    V. Lukashevich, A. Schweizer, Q. Shao, P.H. Groop, W. Kothny, Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. Diabetes Obes. Metab. 13(10), 947–954 (2011)PubMedCrossRefGoogle Scholar
  42. 42.
    V. Lukashevich, A. Schweizer, J. Foley, Q. Shao, P.H. Groop, W. Kothny, Efficacy of vildagliptin therapy in combination with insulin in patients with type 2 diabetes and severe renal impairment. Diabetologia 54, S332–S333 (2011)Google Scholar
  43. 43.
    W. Kothny, A. Schweizer, R. Naik, P.H. Groop, Q. Shao, V. Lukashevich, Comparison of vildagliptin with placebo in a 24-week study of 221 patients with type 2 diabetes and severe renal impairment (eGFR < 30). Diabetologia 54, S332 (2011)Google Scholar
  44. 44.
    H.J. Jeon, T.K. Oh, Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients. Diabetes Metab J 35(5), 529–535 (2011)PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    M. Ito, M. Abe, K. Okada, H. Sasaki, N. Maruyama, M. Tsuchida, T. Higuchi, F. Kikuchi, M. Soma, The dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis. Endocr. J. 58(11), 979–987 (2011)PubMedCrossRefGoogle Scholar
  46. 46.
    J.B. Gruenberger, H. Gilet, L. Esteve, M. Viala-Danten, Association of patient-reported hypoglycemia with health-related quality of life (HRQL) in type 2 diabetes (T2D) patients: results from a clinical trial. Diabetes 60, A549 (2011)CrossRefGoogle Scholar
  47. 47.
    J.E. Foley, M.C. Bunck, D.L. Moller-Goede, M. Poelma, G. Nijpels, E.M. Eekhoff, A. Schweizer, R.J. Heine, M. Diamant, Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 54(8), 1985–1991 (2011)PubMedPubMedCentralCrossRefGoogle Scholar
  48. 48.
    D.R. Matthews, S. Dejager, B. Ahren, V. Fonseca, E. Ferrannini, A. Couturier, J.E. Foley, B. Zinman, Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. Diabetes Obes. Metab. 12(9), 780–789 (2010)PubMedCrossRefGoogle Scholar
  49. 49.
    M. Kikuchi, M. Haneda, D. Koya, K. Tobe, Y. Onishi, A. Couturier, N. Mimori, Y. Inaba, M. Goodman, Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 89(3), 216–223 (2010)PubMedCrossRefGoogle Scholar
  50. 50.
    Y. Iwamoto, A. Kashiwagi, N. Yamada, S. Terao, N. Mimori, M. Suzuki, H. Tachibana, Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. Diabetes Obes. Metab. 12(8), 700–708 (2010)PubMedPubMedCentralCrossRefGoogle Scholar
  51. 51.
    C. Filozof, S. Schwartz, J.E. Foley, Effect of vildagliptin as add-on therapy to a low-dose metformin. World J. Diabetes 1(1), 19–26 (2010)PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    C. Filozof, J.F. Gautier, A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet. Med. 27(3), 318–326 (2010)PubMedCrossRefGoogle Scholar
  53. 53.
    M.A. Banerji, D. Purkayastha, B.H. Francis, Safety and tolerability of vildagliptin vs. thiazolidinedione as add-on to metformin in type 2 diabetic patients with and without mild renal impairment: a retrospective analysis of the GALIANT study. Diabetes Res. Clin. Pract. 90(2), 182–190 (2010)PubMedCrossRefGoogle Scholar
  54. 54.
    B. Ahren, J.E. Foley, E. Ferrannini, D.R. Matthews, B. Zinman, S. Dejager, V.A. Fonseca, Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 33(4), 730–732 (2010)PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    A. Schweizer, S. Dejager, E. Bosi, Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Obes. Metab. 11(8), 804–812 (2009)PubMedCrossRefGoogle Scholar
  56. 56.
    J. Rosenstock, M. Niggli, M. Maldonado-Lutomirsky, Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 11(6), 571–578 (2009)PubMedCrossRefGoogle Scholar
  57. 57.
    J.J. Meier, M. Vollmer, C. Pennartz, C. Abletshauser, W.E. Schmidt, Efficacy and safety of early combination of vildagliptin and metformin in comparison to placebo in patients with type 2 diabetes. Diabetologia 52(S1), S304 (2009)Google Scholar
  58. 58.
    M. Kikuchi, N. Abe, M. Kato, S. Terao, N. Mimori, H. Tachibana, Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 83(2), 233–240 (2009)PubMedCrossRefGoogle Scholar
  59. 59.
    M. Goodman, H. Thurston, J. Penman, Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm. Metab. Res. 41(5), 368–373 (2009)PubMedCrossRefGoogle Scholar
  60. 60.
    B. Francis, D. Purkayastha, M.A. Banerji, Safety of vildagliptin in patients with mild renal impairment and patients with normal renal function: GALIANT study. Can. J. Diabetes 33(3), 288–289 (2009)CrossRefGoogle Scholar
  61. 61.
    J.E. Foley, S. Sreenan, Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm. Metab. Res. 41(12), 905–909 (2009)PubMedCrossRefGoogle Scholar
  62. 62.
    J.E. Foley, S.S. Efficacy, Erratum: safety comparison between the dpp-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm. Metab. Res. 41(12), 909 (2009)CrossRefGoogle Scholar
  63. 63.
    E. Ferrannini, V. Fonseca, B. Zinman, D. Matthews, B. Ahren, S. Byiers, Q. Shao, S. Dejager, Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes. Metab. 11(2), 157–166 (2009)PubMedCrossRefGoogle Scholar
  64. 64.
    E. Bosi, F. Dotta, Y. Jia, M. Goodman, Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 11(5), 506–515 (2009)PubMedCrossRefGoogle Scholar
  65. 65.
    G. Bolli, F. Dotta, L. Colin, B. Minic, M. Goodman, Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes. Metab. 11(6), 589–595 (2009)PubMedCrossRefGoogle Scholar
  66. 66.
    L. Blonde, S. Dagogo-Jack, M.A. Banerji, R.E. Pratley, A. Marcellari, R. Braceras, D. Purkayastha, M. Baron, Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial-a primary care, type 2 diabetes study. Diabetes Obes. Metab. 11(10), 978–986 (2009)PubMedCrossRefGoogle Scholar
  67. 67.
    B. Ahren, J. Foley, E. Ferrannini, D. Matthews, B. Zinman, S. Dejager, V. Fonseca, Changes in prandial glucagon levels after 2 years treatment with vildagliptin or glimepiride. Diabetologia 52(S1), S314 (2009)Google Scholar
  68. 68.
    W.A. Scherbaum, A. Schweizer, A. Mari, P.M. Nilsson, G. Lalanne, Y. Wang, B.E. Dunning, J.E. Foley, Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes. Metab. 10(11), 1114–1124 (2008)PubMedCrossRefGoogle Scholar
  69. 69.
    W.A. Scherbaum, A. Schweizer, A. Mari, P.M. Nilsson, G. Lalanne, S. Jauffret, J.E. Foley, Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes. Metab. 10(8), 675–682 (2008)PubMedCrossRefGoogle Scholar
  70. 70.
    C. Pan, W. Yang, J.P. Barona, Y. Wang, M. Niggli, P. Mohideen, Y. Wang, J.E. Foley, Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. Diabet. Med. 25(4), 435–441 (2008)PubMedCrossRefGoogle Scholar
  71. 71.
    A. Mari, W.A. Scherbaum, P.M. Nilsson, G. Lalanne, A. Schweizer, B.E. Dunning, S. Jauffret, J.E. Foley, Characterization of the influence of vildagliptin on model-assessed beta-cell function in patients with type 2 diabetes and mild hyperglycemia. J. Clin. Endocrinol. Metab. 93(1), 103–109 (2008)PubMedCrossRefGoogle Scholar
  72. 72.
    B. Goke, K. Hershon, D. Kerr, A. Calle Pascual, A. Schweizer, J. Foley, Q. Shao, S. Dejager, Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. Horm. Metab. Res. 40(12), 892–895 (2008)PubMedCrossRefGoogle Scholar
  73. 73.
    A.J. Garber, J.E. Foley, M.A. Banerji, P. Ebeling, S. Gudbjornsdottir, R.P. Camisasca, A. Couturier, M.A. Baron, Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes. Metab. 10(11), 1047–1056 (2008)PubMedCrossRefGoogle Scholar
  74. 74.
    G. Bolli, F. Dotta, E. Rochotte, S.E. Cohen, Efficacy and tolerability of vildagliptin vs pioglitazone when added to metformin: a 24-week, randomized, double-blind study. Diabetes Obes. Metab. 10(1), 82–90 (2008)PubMedGoogle Scholar
  75. 75.
    A. Schweizer, A. Couturier, J.E. Foley, S. Dejager, Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. Diabet. Med. 24(9), 955–961 (2007)PubMedCrossRefGoogle Scholar
  76. 76.
    F.X. Pi-Sunyer, A. Schweizer, D. Mills, S. Dejager, Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. Diabetes Res. Clin. Pract. 76(1), 132–138 (2007)PubMedCrossRefGoogle Scholar
  77. 77.
    A.J. Garber, A. Schweizer, M.A. Baron, E. Rochotte, S. Dejager, Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes. Metab. 9(2), 166–174 (2007)PubMedCrossRefGoogle Scholar
  78. 78.
    V. Fonseca, A. Schweizer, D. Albrecht, M.A. Baron, I. Chang, S. Dejager, Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 50(6), 1148–1155 (2007)PubMedCrossRefGoogle Scholar
  79. 79.
    S. Dejager, S. Razac, J.E. Foley, A. Schweizer, Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. Horm. Metab. Res. 39(3), 218–223 (2007)PubMedCrossRefGoogle Scholar
  80. 80.
    E. Bosi, R.P. Camisasca, C. Collober, E. Rochotte, A.J. Garber, Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 30(4), 890–895 (2007)PubMedCrossRefGoogle Scholar
  81. 81.
    B. Ahren, G. Pacini, A. Tura, J.E. Foley, A. Schweizer, Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. Horm. Metab. Res. 39(11), 826–829 (2007)PubMedCrossRefGoogle Scholar
  82. 82.
    R.E. Pratley, S. Jauffret-Kamel, E. Galbreath, D. Holmes, Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm. Metab. Res. 38(6), 423–428 (2006)PubMedCrossRefGoogle Scholar
  83. 83.
    S. Ristic, S. Byiers, J. Foley, D. Holmes, Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes. Metab. 7(6), 692–698 (2005)PubMedCrossRefGoogle Scholar
  84. 84.
    B. Ahren, G. Pacini, J.E. Foley, A. Schweizer, Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28(8), 1936–1940 (2005)PubMedCrossRefGoogle Scholar
  85. 85.
    B. Ahren, R. Gomis, E. Standl, D. Mills, A. Schweizer, Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27(12), 2874–2880 (2004)PubMedCrossRefGoogle Scholar
  86. 86.
    B. Ahren, J.E. Foley, S. Dejager, M. Akacha, Q. Shao, G. Heimann, M. Dworak, A. Schweizer, Higher risk of hypoglycemia with glimepiride versus vildagliptin in patients with type 2 diabetes is not driven by high doses of glimepiride: divergent patient susceptibilities? Diabetes Ther 5(2), 459–469 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    M.C. Bunck, M. Poelma, D.L. Goede, L.W. Van Golen, R.E. Van Genugten, E.M. Eekhoff, A. Schweizer, R.J. Heine, J.E. Foley, G. Nijpels, M. Diamant. Beta-cell function and glycemic control following one-year vildagliptin treatment, and after 12-week washout, in drug-naive patients with type 2 diabetes and mild hyperglycemia. Paper presented at the The American Diabetes Association 70th Annual Scientific Sessions, Orlando, FloridaGoogle Scholar
  88. 88.
    W. David Strain, V. Lukashevich, W. Kothny, M.J. Hoellinger, P. Paldanius, INdividualised Treatment targets for EldeRly patients using Vildagliptin Add-on or Lone therapy (INTERVAL) study. Diabetologia 56, S354–S355 (2013)Google Scholar
  89. 89.
    W.L. de Ranitz-Greven, J.W. Beulens, L.B. Hoeks, G. Belle-van Meerkerk, D.H. Biesma, H.W. de Valk, Patients with type 2 diabetes mellitus failing on oral agents and starting once daily insulin regimen; a small randomized study investigating effects of adding vildagliptin. BMC Res Notes 7, 579 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    G. Derosa, A. Bonaventura, L. Bianchi, D. Romano, E. Fogari, A. D’Angelo, P. Maffioli, Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metab. Clin. Exp. 63(7), 957–967 (2014)PubMedCrossRefGoogle Scholar
  91. 91.
    G. Derosa, A. Bonaventura, L. Bianchi, D. Romano, E. Fogari, A. D’Angelo, P. Maffioli, Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with Type 2 diabetes. Diabet. Med. 31(12), 1515–1523 (2014)PubMedCrossRefGoogle Scholar
  92. 92.
    M. Hassanein, K. Abdallah, A. Schweizer, A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc. Health Risk Manag. 10, 319–326 (2014)PubMedPubMedCentralGoogle Scholar
  93. 93.
    W. Kothny, J. Foley, A. Schweizer, M.S. Rendell, V. Lukashevich, Efficacy of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment. Diabetologia 57, S357–S358 (2014)Google Scholar
  94. 94.
    V. Lukashevich, S.D. Prato, M. Araga, W. Kothny, Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes. Metab. 16(5), 403–409 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    P. Maffioli, A. Bonaventura, L. Bianchi, D. Romano, E. Fogari, A. D’Angelo, G. Derosa, Comparison of vildagliptin and glimepiride: effects on glycemic control, fat tolerance, and inflammatory markers in people with type 2 diabetes. Diabetes 63, A277 (2014)Google Scholar
  96. 96.
    M. Odawara, I. Hamada, M. Suzuki, Efficacy and safety of vildagliptin as add-on to metformin in japanese patients with type 2 diabetes mellitus. Diabetes Ther 5(1), 169–181 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    H.J. Strotmann, D. Goetze, C. Koch, T. Forst, Vildagliptin versus insulin as add-on therapy to glimepiride in type 2 diabetes mellitus: results from a randomised controlled trial. Diabetologia 1, S364–S365 (2014)Google Scholar
  98. 98.
    G. Ning, W. Wang, L. Li, J. Ma, X. Lv, M. Yang, W. Wang, M. Woloschak, V. Lukashevich, W. Kothny, Vildagliptin as add-on therapy to insulin improves glycemic control without increasing risk of hypoglycemia in Asian, predominantly Chinese, patients with type 2 diabetes mellitus. J. Diabetes (2015). doi: 10.1111/1753-0407.12303 Google Scholar
  99. 99.
    W. Yang, X. Xing, X. Lv, Y. Li, J. Ma, G. Yuan, F. Sun, W. Wang, M. Woloschak, V. Lukashevich, P. Kozlovski, W. Kothny, Vildagliptin added to sulfonylurea improves glycemic control without hypoglycemia and weight gain in Chinese patients with type 2 diabetes mellitus. J. Diabetes 7(2), 174–181 (2015)PubMedCrossRefGoogle Scholar
  100. 100.
    T. Forst, C. Koch, M. Dworak, Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study. Curr. Med. Res. Opin. 31(6), 1079–1084 (2015)PubMedCrossRefGoogle Scholar
  101. 101.
    A.R. Hong, J. Lee, E.J. Ku, Y. Hwangbo, K.M. Kim, J.H. Moon, S.H. Choi, H.C. Jang, S. Lim, Comparison of vildagliptin as an add-on therapy and sulfonylurea dose-increasing therapy in patients with inadequately controlled type 2 diabetes using metformin and sulfonylurea (VISUAL study): a randomized trial. Diabetes Res. Clin. Pract. 109(1), 141–148 (2015)PubMedCrossRefGoogle Scholar
  102. 102.
    M. Macauley, K.G. Hollingsworth, F.E. Smith, P.E. Thelwall, A. Al-Mrabeh, A. Schweizer, J.E. Foley, R. Taylor, Effect of vildagliptin on hepatic steatosis. J. Clin. Endocrinol. Metab. 100(4), 1578–1585 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Y. Takeshita, T. Takamura, Y. Kita, T. Otoda, K.I. Kato, H. Wakakuri, M. Yamada, H. Misu, Y. Matsushima, S. Kaneko, Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study. J. Diabetes Investig. 6(2), 192–200 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    I. Zografou, C. Sampanis, E. Gkaliagkousi, F. Iliadis, A. Papageorgiou, P. Doukelis, K. Vogiatzis, S. Douma, Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus. Hormones 14(1), 118–125 (2015)PubMedGoogle Scholar
  105. 105.
    A. Strozik, A. Steposz, M. Basiak, M. Drozdz, B. Okopien, Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus. Pharmacol. Rep. 67(1), 24–31 (2015)PubMedCrossRefGoogle Scholar
  106. 106.
    G. Ning, L. Li, J. Ma, X. Lv, M. Yang, W. Wang, M. Woloschak, V. Lukashevich, W. Kothny, Vildagliptin as add-on to insulin improves glycaemic control without increased risk of hypoglycaemia in Asian (predominantly Chinese) patients with type 2 diabetes mellitus. Diabetologia 57, S330 (2014)Google Scholar
  107. 107.
  108. 108.
  109. 109.
  110. 110.
  111. 111.
  112. 112.
  113. 113.
  114. 114.
  115. 115.
  116. 116.
    W. Kothny, V. Lukashevich, J.E. Foley, M.S. Rendell, A. Schweizer, Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia 58(9), 2020–2026 (2015)PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
  118. 118.
    C.J. Li, X.J. Liu, L. Bai, Q. Yu, Q.M. Zhang, P. Yu, D.M. Yu, Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol. Metab. Syndr. 6(1), 69 (2014)PubMedPubMedCentralCrossRefGoogle Scholar
  119. 119.
    J. Rosenstock, M.A. Baron, S. Dejager, D. Mills, A. Schweizer, Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 30(2), 217–223 (2007)PubMedCrossRefGoogle Scholar
  120. 120.
    J. Rosenstock, M.A. Baron, S. Dejager, D. Mills, A. Schweizer, Erratum: comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: A 24-week, double-blind, randomized trial (Diabetes Care (2007) 30 (217–223)). Diabetes Care 30(5), 1330 (2007)Google Scholar
  121. 121.
    W. Kothny, J. Foley, P. Kozlovski, Q. Shao, B. Gallwitz, V. Lukashevich, Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus. Diabetes Obes. Metab. 15(3), 252–257 (2013)PubMedCrossRefGoogle Scholar
  122. 122.
    A. Strozik, A. Steposz, B. Okopien, Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus. Diabetes 62, A668 (2013)Google Scholar
  123. 123.
    I. Zografou, C. Sampanis, A. Papageorgiou, B. Nikolaidou, P. Doukelis, D. Papadopoulou, M. Doumas, S. Douma, The effect of vildagliptin on arterial stiffness in drug naive patients with type 2 diabetes mellitus. Diabetes 62, A596 (2013)Google Scholar
  124. 124.
    M. Haidinger, J. Werzowa, M. Hecking, M. Antlanger, G. Stemer, J. Pleiner, C. Kopecky, J.J. Kovarik, D. Doller, G. Pacini, M.D. Saemann, Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation-a randomized, double-blind, placebo-controlled trial. Am. J. Trans. 14(1), 115–123 (2014)CrossRefGoogle Scholar
  125. 125.
    M. Haidinger, J. Werzowa, M. Hecking, G. Stemer, J. Pleiner, C. Kopecky, G. Pacini, M. Antlanger, M.D. Saemann, Vildagliptin in new-onset diabetes after kidney transplantation is safe and efficencient-results from the viennavinodat trial. Nephrol. Dial. Trans. 28, i77 (2013)CrossRefGoogle Scholar
  126. 126.
    M. Haidinger, J. Werzowa, M. Hecking, G. Pacini, M. Antlanger, J. Kovarik, Efficacy and safety of vildagliptin in newly diagnosed diabetes after kidney transplantation: results from the Vienna VINODAT trial. Wien. Klin. Wochenschr. 25, S19–S20 (2013)Google Scholar
  127. 127.
    M. Haidinger, J. Werzowa, H.C. Voigt, J. Pleiner, G. Stemer, M. Hecking, D. Doller, W.H. Horl, T. Weichhart, M.D. Saemann, A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials 11, 91 (2010)PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    W.D. Strain, V. Lukashevich, W. Kothny, M.J. Hoellinger, P.M. Paldanius, Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 382(9890), 409–416 (2013)PubMedCrossRefGoogle Scholar
  129. 129.
  130. 130.
    FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. http://www.fda.gov/Drugs/DrugSafety/ucm459579.htm (2015). Accessed 29 August 2015
  131. 131.
    J.B. Green, M.A. Bethel, P.W. Armstrong, J.B. Buse, S.S. Engel, J. Garg, R. Josse, K.D. Kaufman, J. Koglin, S. Korn, J.M. Lachin, D.K. McGuire, M.J. Pencina, E. Standl, P.P. Stein, S. Suryawanshi, F. Van de Werf, E.D. Peterson, R.R. Holman, Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. (2015). doi: 10.1056/NEJMoa1501352 PubMedCentralGoogle Scholar
  132. 132.
    B.M. Scirica, D.L. Bhatt, E. Braunwald, P.G. Steg, J. Davidson, B. Hirshberg, P. Ohman, R. Frederich, S.D. Wiviott, E.B. Hoffman, M.A. Cavender, J.A. Udell, N.R. Desai, O. Mosenzon, D.K. McGuire, K.K. Ray, L.A. Leiter, I. Raz, Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369(14), 1317–1326 (2013)PubMedCrossRefGoogle Scholar
  133. 133.
    W.B. White, C.P. Cannon, S.R. Heller, S.E. Nissen, R.M. Bergenstal, G.L. Bakris, A.T. Perez, P.R. Fleck, C.R. Mehta, S. Kupfer, C. Wilson, W.C. Cushman, F. Zannad, Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369(14), 1327–1335 (2013)PubMedCrossRefGoogle Scholar
  134. 134.
    D.R. Matthews, A. Tsapas, Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diabetes Vasc. Dis. Res. 5(3), 216–218 (2008)CrossRefGoogle Scholar
  135. 135.
    K. Krum, V. Lukashevich, G.B. Bolli, P. Kozlovski, W. Kothny, P. Ponikowski. No Significant Difference in Risk of Heart Failure Hospitalization with Vildagliptin in Diabetic Patients with Systolic Chronic Heart Failure: VIVIDD. Paper presented at the The American Diabetes Association 74th Annual Scientific Sessions, San Francisco, California, June 13–17Google Scholar
  136. 136.
    J. McMurray. The vildagliptin in ventricular dysfunction diabetes (VIVIDD) trial. Paper presented at the Heart Failure Congress, Lisbon, Portugal, May 25–28Google Scholar
  137. 137.
    M. Evans, G. McInnes, M. Stumvoll, S. Del Prato, A. Schweizer, Q. Shao, V. Lukashevich, W. Kothny, Assessment of heart failure risk with vildagliptin in diabetic patients: pooled analysis of safety data from approximately 17,000 patients. Diabetologia 57(1 SUPPL. 1), S361 (2014)Google Scholar
  138. 138.
    M. Monami, I. Dicembrini, E. Mannucci, Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr. Metab. Cardiovasc. Dis. 24(7), 689–697 (2014)PubMedCrossRefGoogle Scholar
  139. 139.
    G. McInnes, M. Evans, S. Del Prato, M. Stumvoll, A. Schweizer, V. Lukashevich, Q. Shao, W. Kothny. Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17000 patients. Diabetes Obes Metab (2015)Google Scholar
  140. 140.
    Guidance for Industry Diabetes Mellitus—Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. In: Services, U.S.D.o.H.a.H. (ed.) Federal Register: The daily journal of the United States Government, vol. 18 June 2015. (Food and Drug Administration, 2008)Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Eleni Bekiari
    • 1
    • 2
  • Chrysoula Rizava
    • 1
  • Eleni Athanasiadou
    • 1
  • Konstantinos Papatheodorou
    • 2
    • 3
  • Aris Liakos
    • 1
  • Thomas Karagiannis
    • 1
  • Maria Mainou
    • 1
  • Maria Rika
    • 2
  • Panagiota Boura
    • 4
  • Apostolos Tsapas
    • 1
    • 2
    • 5
  1. 1.Clinical Research and Evidence-Based Medicine Unit, Second Medical DepartmentAristotle University ThessalonikiThessaloníkiGreece
  2. 2.Diabetes Centre, Second Medical DepartmentAristotle University ThessalonikiThessaloníkiGreece
  3. 3.Second Medical DepartmentDemocritus University ThraceAlexandroupoliGreece
  4. 4.Second Medical DepartmentAristotle University ThessalonikiThessaloníkiGreece
  5. 5.Harris Manchester CollegeUniversity of OxfordOxfordUK

Personalised recommendations